Cocrystal Pharma (COCP) EBITDA Yield: History & Chart

Cocrystal Pharma, Inc.(COCP)

Biotechnology · Bothell, WA

$1.110.00 (0.00%)

Delayed quote: Oct 6, 2026, 11:54 AM EDT

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

Bothell, WA

10 employees

www.cocrystalpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James E. Sapirstein

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Cocrystal Pharma, Inc. (COCP)	$15.30M	N/A	N/A	N/A	N/A
Pasithea Therapeutics Corp. (KTTA)vs ›	$15.25M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.07M	N/A	N/A	N/A	N/A
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.75M	N/A	N/A	N/A	N/A
BioCardia, Inc. (BCDA)vs ›	$16.08M	N/A	7.50%	7.48%	7.48%
Obsidian Therapeutics Inc. (OBX)vs ›	$14.51M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.44M	N/A	N/A	N/A	N/A
Dyadic International, Inc. (DYAI)vs ›	$16.49M	N/A	1.21%	1.72%	1.72%
Vyome Holdings, Inc. (HIND)vs ›	$13.97M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.90M	N/A	0.87%	0.87%	0.87%

NAME

MARKET CAP

EBITDA YIELD

TTM

Cocrystal Pharma, Inc. (COCP)

$15.30M

N/A

Pasithea Therapeutics Corp. (KTTA)vs ›

$15.25M

N/A

Karyopharm Therapeutics Inc. (KPTI)vs ›

$15.07M

N/A

Allarity Therapeutics, Inc. (ALLR)vs ›

$15.75M

N/A

BioCardia, Inc. (BCDA)vs ›

$16.08M

N/A

7.50%

7.48%

Obsidian Therapeutics Inc. (OBX)vs ›

$14.51M

N/A

Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›

$14.44M

N/A

Dyadic International, Inc. (DYAI)vs ›

$16.49M

N/A

1.21%

1.72%

Vyome Holdings, Inc. (HIND)vs ›

$13.97M

N/A

Citius Pharmaceuticals, Inc. (CTXR)vs ›

$13.90M

N/A

0.87%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

COCP EBITDA Yield Metrics

COCP Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics